PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.70%
Operating income growth above 1.5x RVPH's 7.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-117.18%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-117.27%
Negative EPS growth while RVPH is at 7.69%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-117.27%
Negative diluted EPS growth while RVPH is at 7.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.72%
Negative OCF growth while RVPH is at 38.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-138.72%
Negative FCF growth while RVPH is at 38.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.97%
OCF/share CAGR of 64.97% while RVPH is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
64.97%
5Y OCF/share CAGR above 1.5x RVPH's 21.52%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
27.61%
3Y OCF/share CAGR at 50-75% of RVPH's 53.59%. Martin Whitman would suspect weaker recent execution or product competitiveness.
64.19%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
64.19%
5Y net income/share CAGR similar to RVPH's 60.51%. Walter Schloss might see both on parallel mid-term trajectories.
-5.53%
Negative 3Y CAGR while RVPH is 58.01%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.11%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.50%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.